India missed its target of eliminating tuberculosis (TB) by 2025, five years before the global Sustainable Development Goal deadline of 2030. The WHO Global Tuberculosis Report 2026, released in November, recorded a 38% fall in Indian TB deaths between 2015 and 2025, from 28 to 18 per lakh population, compared with a global decline of 35%.
Mortality and treatment progress
The reduction met the WHO End TB Strategy’s interim 2020 milestone of a 35% fall in deaths, but not its 2025 target of 75%. India accounted for about 25% of global TB cases and 23% of deaths in 2025, retaining the largest national disease burden. Treatment success for drug-susceptible TB was 94%. The report omitted India’s latest incidence estimates pending review of district-level surveillance data; updated estimates are expected in early 2027.
National interventions and screening
The Union Ministry of Health and Family Welfare attributed progress to National TB Elimination Programme measures, including proactive case finding, AI-enabled X-rays, rapid diagnostics and nutritional support through Ni-kshay Poshan Yojana and Ni-kshay Mitra. From 7 December 2024 to 8 November 2026, TB Mukt Bharat Abhiyaan screened over 25 crore people, conducted more than 11 crore chest X-rays and over 3 crore nucleic acid amplification tests. It identified 48.64 lakh new cases, including 14.97 lakh asymptomatic cases. Domestic resources meet 96% of TB programme funding requirements.
Important Facts for Exams
- Programme hierarchy: The National Tuberculosis Elimination Programme operates through national, state, district and sub-district tiers, with Tuberculosis Units at block level.
- Laboratory tiers: Its diagnostic network has three tiers: frontline microscopy and rapid molecular testing, intermediate reference and culture labs, and national reference laboratories for quality assurance.
- Rapid resistance testing: The rapid molecular tests CBNAAT and TruNat can diagnose tuberculosis and detect resistance to rifampicin, an important drug-resistance marker.






